arrow
A

Andreas Peyrl

Medical University of Vienna
H指数:29
被引数:3,448

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nanopore-based liquid biopsy analysis enables preoperative tumor classification in pediatric brain tumors

基于纳米孔的液体活检分析能够实现儿童脑肿瘤的术前肿瘤分类

2026-08-010
OA
Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI

评估复发性髓母细胞瘤对治疗的反应:使用颅脑脊髓MRI

2026-07-010
PRE
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma

联合靶向CDK4/6和MEK逆转治疗耐药型BRAF突变型儿童高级别胶质瘤的间充质转化

2026-05-160
OAAI
Impact of Bevacizumab treatment intervals on surgical interventions in pediatric neuro-oncology

贝伐珠单抗治疗间隔对儿科神经肿瘤学中手术干预的影响

2026-01-010
PRE
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions

胚胎性多层层状-rosettes肿瘤的细胞层次结构由致癌microRNAs和受体-配体相互作用塑造。

2025-05-260
OA
Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method

脑肿瘤患者液体活检中H3F3A K27M或BRAF V600E的检测作为诊断和监测生物标志物:肿瘤定位和采样方法的影响

2025-01-030
OA
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
2024-11-180
PRE
Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma
2024-07-101
OAAI
FEASIBILITY, TOLERABILITY AND FIRST EXPERIENCE OF INTRACYSTIC TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CYSTIC CRANIOPHARYNGIOMA
2024-06-180
OAAI
PRE-OPERATIVE TUMOUR CLASSIFICATION USING NANOPORE SEQUENCING OF CEREBROSPINAL FLUID
2024-06-180
OAAI